Drug interactions
Empagliflozin-linagliptin + Glecaprevir / pibrentasvir
Severity: Minor
Empagliflozin-linagliptin and Glecaprevir / pibrentasvir: minor interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Glecaprevir and pibrentasvir inhibit P-glycoprotein and may raise linagliptin concentrations. Linagliptin has a wide safety margin, so clinically important effects are unlikely. Glycemic control may also change as hepatitis C is treated.
What this interaction means in plain words
Empagliflozin-linagliptin and Glecaprevir / pibrentasvir have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised.
Why it happens
Inhibition of intestinal P-glycoprotein increases linagliptin absorption.
What to do
No dose change is needed; monitor blood glucose during and after hepatitis C treatment.
What to ask your pharmacist
- Is there anything I should notice while taking both?
- Do I need to tell my doctor at the next visit?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Glecaprevir / pibrentasvir, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Frequently asked questions
Can I take Empagliflozin-linagliptin with Glecaprevir / pibrentasvir?
MediHelp rates the interaction as minor. Empagliflozin-linagliptin and Glecaprevir / pibrentasvir have a small, usually unimportant interaction. Most people can take both; the pharmacist may still mention it so that any unexpected effect is recognised. Glecaprevir and pibrentasvir inhibit P-glycoprotein and may raise linagliptin concentrations. Linagliptin has a wide safety margin, so clinically important effects are unlikely. Glycemic control may also change as hepatitis C is treated.
How serious is the interaction between Empagliflozin-linagliptin and Glecaprevir / pibrentasvir?
MediHelp rates it minor, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: No dose change is needed; monitor blood glucose during and after hepatitis C treatment.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
